A new way of selecting treatments for terminal pancreatic cancer patients may have been uncovered by researchers at the University of Birmingham and collaborators.
Using cells from twelve patients, the research team created a single-cell map of tumor-infiltrating immune cells and peripheral immune cells, coupled with gene expression, single-cell TCR and BCR sequencing, and identifying proteins expressed on these cells. The team then verified their findings using two other large publicly available pancreatic cancer datasets.
Their work was published in Nature Communications. The lead author is Shivan Sivakumar, PhD, FRCP, of the University of Birmingham.
Pancreatic ductal adenocarcinoma (PDAC) has the worst survival of any common human cancer, with a five-year survival of below 10%….